Viritis

Company Overview

Snapshot

Founded in August 2020 by Aaron Wis, Amit Turman, and Amit Philosoph, Viritis operates with 1–10 employees. The company has raised $665,000 across 4 funding rounds from 2 investors. In February 2025, Viritis secured a grant, highlighting its ongoing development in antiviral treatments.

Business overview

Viritis is a biotech company specializing in a next-generation antisense-based platform for the rapid development of antiviral drugs. Its core technology utilizes AI-driven algorithms and patented molecule design to specifically bind to viral RNA, activating cellular defense mechanisms to degrade the virus without harming the host. The platform serves the pharmaceutical and biotechnology industries, aiming to provide scalable and precise solutions for current and emerging viral threats, with molecules designed to naturally disintegrate post-function.

Strategic signal

In September 2025, Nature Biotechnology highlighted Viritis's innovative use of AI to design antiviral antisense therapy drugs. This recognition from a prominent scientific publication validates the company's technological approach and signals its potential to significantly impact the development of antiviral treatments, attracting further interest from the scientific community and potential investors in the biopharmaceutical sector.

Company Intelligence Q&A

What is Viritis's core technological approach?

Viritis pioneers a next-generation antisense-based platform that uses AI-driven algorithms and patented molecule design to target and degrade viral RNA within cells, activating innate defense mechanisms without harming the host.

When was Viritis founded and by whom?

Viritis was founded in August 2020 by Aaron Wis, Amit Turman, and Amit Philosoph.

How much capital has Viritis raised to date?

Viritis has raised a total of $665,000 across four funding rounds.

What was a key development for Viritis in February 2025?

In February 2025, Viritis secured a grant and also received an investment from Road2.

What recognition did Viritis receive in September 2025?

In September 2025, Nature Biotechnology featured Viritis, acknowledging its use of AI in designing antiviral antisense therapy drugs.